Targeting CHK2 to reduce the expression of BQ323636.1 in ER+ breast cancer to reverse tamoxifen resistance

View Statistics Email Alert RSS Feed

Grant Data
Project Title
Targeting CHK2 to reduce the expression of BQ323636.1 in ER+ breast cancer to reverse tamoxifen resistance
Principal Investigator
Dr Tsoi, Ho   (Principal Investigator (PI))
Co-Investigator(s)
Professor Khoo Ui Soon   (Co-Investigator)
Duration
24
Start Date
2020-06-01
Amount
1227363
Conference Title
Targeting CHK2 to reduce the expression of BQ323636.1 in ER+ breast cancer to reverse tamoxifen resistance
Presentation Title
Keywords
BQ323636.1, Breast cancer, CCT241533, CHK2, prexasertib, tamoxifen
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
07182046
Grant Type
Health and Medical Research Fund - Full Grant
Funding Year
2019
Status
On-going
Objectives
We have previously confirmed BQ323636.1 (BQ) conferred tamoxifen resistance. We found that tamoxifen treatment activated the ATM/CHK2 axis to mediate BQ production. We aim to determine the effect of targeting CHK2 on reducing tamoxifen resistance.